Skip to main content

Table 1 Comparison of demographic and post-transplant characteristics between patients maintaining a full dose and patients with at least one dose reduction in trimethoprim-sulfamethoxazole in the first 12 months post-kidney transplantation

From: Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

Parameter Full Dose Group (N = 233) Reduced Dose Group (N = 205) P value
Age at transplantation (years) (mean ± SD, range) 52.5 ± 13 (19–81) 54.1 ± 12 (24–76) 0.22
Sex (N, %)    0.42
Male 144 (62) 119 (58)  
Female 89 (38) 86 (42)  
Donor Source (N, %)    0.002
Deceased 142 (61) 154 (75)  
Live 91 (39) 51 (25)  
Number of transplants    0.4
One 224 (97) 194 (96)  
Two 7 (3) 9 (4)  
Cause of end-stage kidney disease (N, %)
 Diabetes 41 (18) 44 (22) 0.30
 Hypertension 25 (11) 19 (9) 0.61
 Glomerulonephritis 94 (40) 78 (38) 0.62
 Polycystic kidney disease 23 (10) 28 (14) 0.21
 Congenital kidney disease 10 (4) 7 (3) 0.63
 Others 40 (17) 29 (14) 0.28
Ethnicity
 Caucasian 94 (40) 70 (34) 0.13
 Black 16 (7) 21 (10) 0.20
 East Asian 32 (14) 20 (10) 0.19
 South Asian 47 (20) 53 (26) 0.15
 Other 43 (19) 41 (20) 0.71
Pre-transplant dialysis modality (N, %)    0.015
Hemodialysis 122 (53) 131 (64)  
Peritoneal dialysis 69 (30) 54 (27)  
Preemptive 36 (17) 18 (9)  
Dialysis duration (days) (mean ± SD) 1790 ± 1315 2052 ± 1427 0.06
Cytomegalovirus IgG antibody N (%) 174 (75) 167 (81) 0.18
Epstein Barr virus IgG antibody N (%) 211 (91) 189 (93) 0.70
Hepatitis B surface antigen N (%) 4 (2) 3 (1) 0.29
Hepatitis C antibody N (%) 4 (2) 2 (1) 0.41
HIV antibody N (%) 2 (1) 4 (2) 0.29
Tuberculin skin test positive N (%) 31 (13) 11 (5) 0.33
Cumulative Panel Reactive Antibody (%)(mean ± SD, range) 7.5 ± 20 (0–99) 13.5 ± 28 (0–100) 0.02
History of smoking (N, %) 94 (42) 56 (28) 0.003
Delayed graft function N (%) 38 (16) 41 (20) 0.31
Acute rejection N (%) 7 (3) 18 (9) 0.009
Post-transplant diabetes (N, %) 19 (8) 16 (8) 0.81
Graft loss N (%) 2 (1) 0 (0) 0.28
Immunosuppressive medication at discharge (N, %)
 Tacrolimus 215 (93) 189 (93) 0.99
 Cyclosporine 11 (5) 14 (7) 0.34
 Mycophenolate mofetil 104 (45) 80 (39) 0.23
 or mycophenolic acid 103 (45) 95 (44) 0.64
 Azathioprine 11 (5) 4 (2) 0.09
 Prednisone 219 (95) 196 (97) 0.37
Other medication (N, %)
 Angiotensin-converting enzyme inhibitor 12 (5) 9 (4) 0.71
 Angiotensin II receptor blocker 19 (8) 24 (12) 0.21
 Non-dihydropyridine calcium channel blocker 21 (9) 13 (6) 0.28
 Dihydropyridine calcium channel blocker 100 (43) 100 (49) 0.21
 Beta blocker 87 (37) 90 (44) 0.15
 Alpha blocker 23 (10) 19 (9) 0.83
 Loop diuretic 10 (4) 12 (6) 0.29
 Thiazide diuretic 4 (2) 4 (2) 0.56
  1. Abbreviations: IgG immunoglobulin G, SD standard deviation